Pathway for Evaluation and Treatment of
Kawasaki Disease or Incomplete Kawasaki Disease
Consider KD for:
Patients with ≥ 3 days of fever and any principal clinical features of KD
OR
Infants ≤ 6 months with ≥ 7 days of unexplained fever
Adapted from 2017 AHA KD Guidelines
Clinical decision-making should be individualized to specific patient circumstances
arrow
  • FLOC/RN Team Assessment
  • History & Physical, Clinical Criteria
    • Assess for presence of clinical criteria at any time during current febrile illness
  • Laboratory Testing
    • Lab testing if H&P consistent with complete or incomplete KD.
    • Consider lab testing if 3 days of fever and strong clinical suspicion for KD.
arrow
arrow
arrow
arrow
arrow
arrow
arrow
Complete Kawasaki Disease
  • Use Incomplete Kawasaki Disease Algorithm to determine need for further evaluation and treatment
  • Fever ≥ 5 days and ≥ 4 principal clinical features
  • OR
  • Fever ≥ 4 days and 5 principal clinical features
  • Evaluate as clinically indicated
  • Consider pitfalls in KD diagnosis
  • Admit/discharge as clinically indicated
arrow
Admit and Treat
arrow
arrow
arrow
Admit for further evaluation
Possible treatment
Discharge
Follow up in 24 hours
arrow
Initial Treatment
Initial treatment for KD includes IVIG, ASA (high or low dose), +/- Steroids
arrow
arrow
Age ≤ 6 months
Age > 6 months
arrow
arrow
Monitor response to treatment
Review echo results, discuss with cardiology
Further management based on echo results and initial treatment response for all ages
arrow
arrow
Discuss all abnormal echocardiogram results with Cardiology.
  • Principal Clinical Features of KD
    • May not all be present at the same time
  • Oral changes
    • Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa
  • Conjunctivitis
    • Bilateral bulbar conjunctival injection without exudate
  • Rash
    • Maculopapular, diffuse erythroderma, or erythema multiforme-like
  • Extremity changes
    • Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase
  • Lymphadenopathy
    • Cervical lymphadenopathy (≥ 1.5 cm diameter), usually unilateral
See AHA Guidelines Page e935, Figure 2. Clinical features of classic Kawasaki disease
  • Pitfalls in KD Diagnosis
  • Consider KD for:
    • Infants < 6 months w/ prolonged fever and irritability
    • Infants with prolonged fever and unexplained aseptic meningitis
    • Infants/children with prolonged fever and any of the following:
      • Unexplained or culture negative shock
      • Cervical lymphadenitis unresponsive to antibiotic therapy
      • Retropharyngeal or parapharyngeal phlegmon unresponsive to antibiotic therapy
  • Documented viral or bacterial (e.g. strep) may co-exist in patients with KD
  • KD with Shock OR
    KD with Macrophage Activation Syndrome
  • Consult Rheumatology and Cardiology.
  • Timely management with IVIG and additional treatments.
  • Consider ICU consult and/or management.
Posted: January 2018
Revised: February 2018
Authors: D. Whitney, MD; K. Dorland, BSN; J. Beus, MD; J. Brothers, MD; L. Buckley, MD; S. Burnham MD; D. Campeggio, MSN; K. DiPasquale, MD; M. Fein, MD; H. Ghanem MD; J. Hart MD; J. Lavelle, MD; C. Law PharmD; S. Mehta, MD; S. Natarajan, MD; J. Ronan, MD; V. Scheid, MD; S. Swami, MD; H. Vaswani, CRNP
Learn More